Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 24, 2011, reports the results of Jazz Pharmaceuticals, Inc.'s 2011 Annual Meeting of Stockholders held at its Palo Alto, California headquarters. The filing details the voting outcomes for five proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders representing 34,452,087 of the 40,671,360 eligible shares voted on the following matters:
- Proposal 1 (Election of Directors): Paul L. Berns, Bryan C. Cressey, and Patrick G. Enright were elected as Class I directors for three-year terms.
- Proposal 2 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2011.
- Proposal 3 (Equity Plan Criteria): Shareholders approved the Section 162(m) performance criteria and award limits under the 2007 Equity Incentive Plan.
- Proposal 4 (Executive Compensation): The advisory vote on named executive officer compensation was approved.
- Proposal 5 (Compensation Vote Frequency): Shareholders indicated a preference for a three-year frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Management Commentary
Based on the results of Proposal 5, the Board of Directors resolved on May 24, 2011, to hold an advisory vote on the compensation of named executive officers every three years. The filing contains no financial guidance, risk factors, or contingencies.
Key Facts for Investor Verification
- Verify the specific terms of the 2007 Equity Incentive Plan approved under Proposal 3.
- Confirm the composition of the Board of Directors following the election of the three new Class I directors.
- Review the definitive proxy statement dated April 8, 2011, for detailed executive compensation data referenced in Proposal 4.